About Low-density lipoprotein receptor class A domain-containing protein 1
Low-density lipoprotein receptor class A domain-containing protein 1 (LDLRAD1) is a protein
from Homo sapiens identified by UniProt accession
Q5T700, 205 residues long.
MolForge cross-references it against 0 known binders and
24 disease associations.
Target properties
| Protein name | Low-density lipoprotein receptor class A domain-containing protein 1 |
|---|
| UniProt accession | Q5T700 |
|---|
| Gene | LDLRAD1 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 205 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (24)
Diseases linked to this target (Open Targets).
- mean corpuscular volume · score 0.24
- mean corpuscular hemoglobin · score 0.23
- mean corpuscular hemoglobin concentration · score 0.13
- erythrocyte count · score 0.12
- red blood cell density measurement · score 0.11
- linear atrophoderma of Moulin · score 0.07
- familial generalized lentiginosis · score 0.07
- familial progressive hyperpigmentation · score 0.07
- acroleukopathy, symmetric · score 0.07
- Dowling-Degos disease 1 · score 0.07
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q5T700-F1 | alphafold | PREDICTED | 82.66 | — |
Amino-acid sequence (205 residues)
MNKVFPQGEN GYTAAESKAH PGGEAGGGHL CCSRRGACLS ASLLLLLATV AALIALVTIL GLPSCTPGAQ ACITLTNRTG FLCHDQRSCI PASGVCDGVR TCTHGEDEDE SLCRDVPQSL PHFLVAHCGD PASWIYSDQK CDGTNNCGDC SDELSPVTVC PPCGPGWWRC PSTFFKYCDC IPRHLCRDHV QHCSDWSDEY ACPGP
Explore Low-density lipoprotein receptor class A domain-containing protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets